<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426361</url>
  </required_header>
  <id_info>
    <org_study_id>108464</org_study_id>
    <nct_id>NCT00426361</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects</brief_title>
  <official_title>A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and
      thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical
      cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescents
      platform. Therefore, this Phase IIIb study is designed to evaluate the safety and
      immunogenicity of co-administering Boostrix polio (dTpa-IPV) with GSK Biologicals'
      (580299)HPV-16/18 L1 AS04 vaccine (Cervarix TM) as compared to the administration of either
      vaccine alone.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 13, 2007</start_date>
  <completion_date type="Actual">July 25, 2008</completion_date>
  <primary_completion_date type="Actual">March 17, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected Against Diphtheria and Tetanus</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Seroprotection against diphtheria and tetanus is defined as anti-diphtheria and anti-tetanus antibody titres greater than or equal to 0.1 International Units per Milliliter (≥ 0.1 IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin Toxoid (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Titers are given as geometric mean titers (GMTs) calculated on all subjects and expressed as Enzyme-linked Immunosorbent Assay Units per Milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected Against Poliovirus Type 1 (Polio 1), Polio 2 and Polio 3</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Seroprotection against polio 1, 2 and 3 is defined as anti-polio 1, 2 and 3 antibody titers greater than or equal to 8 Effective Dose 50% (≥ 8 ED50).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-HPV-18 Antibodies After Completing the Cervarix Vaccination Course</measure>
    <time_frame>One month post Cervarix Dose 3 (Month 7/8)</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies After Incomplete Cervarix Vaccination Course</measure>
    <time_frame>One month post Dose 1</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies After Completing the Cervarix Vaccination Course</measure>
    <time_frame>One month post Cervarix Dose 3 (Month 7/8)]</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-diphtheria and Anti-tetanus Antibodies</measure>
    <time_frame>One month after vaccination with Boostrix-Polio</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) and expressed as IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibody Titers Above 1.0 International Units Per Milliliter (IU/mL)</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed include 1.0 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-poliovirus Type 1 (Anti-polio 1), Anti-polio 2 and Anti-polio 3 Antibody Titers</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs). The titer is a serum dilution giving 50 percent reduction of signal compared to control without serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Booster Response to Diphtheria and Tetanus</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Booster responses to diphtheria and tetanus were defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off value of 0.1 International Units per Milliliter): antibody titers at least four times the cut-off (post-vaccination titer greater than or equal to 0.4 IU/mL), and
For initially seropositive subjects (pre-vaccination titer greater than or equal to 0.1 IU/mL): an increase in antibody titers of at least four times the pre-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Booster Response to Pertussis Toxoid (PT), Pertactin Toxoid (PRN) and Filamentous Hemagglutinin (FHA)</measure>
    <time_frame>One month after vaccination with Boostrix Polio</time_frame>
    <description>Booster response to PT, FHA and PRN were defined as:
For initially seronegative subjects [pre-vaccination titer below cut-off value of 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)]: antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer above 20 EL.U/mL: an increase in antibody titers of at least 2 times the pre-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms</measure>
    <time_frame>During the 7-day period (Day 0-6) following each vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.
Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>During the 30-day period (Day 0-29) following vaccination</time_frame>
    <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (MSAEs)</measure>
    <time_frame>During the active phase of the study (up to Month 7/8) and during the safety follow-up (up to Month 12/13)</time_frame>
    <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes. MSAEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the active phase of the study (up to Month 7/8) and during the safety follow-up (up to Month 12/13)</time_frame>
    <description>Serious adverse events assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">751</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boostrix Polio → Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix + Boostrix Polio Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix ® Polio</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>Boostrix Polio → Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Boostrix Polio Group</arm_group_label>
    <other_name>dTPa-IPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)</intervention_name>
    <description>Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_label>Boostrix Polio → Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Boostrix Polio Group</arm_group_label>
    <other_name>GlaxoSmithKline (GSK) Biologicals' HPV vaccine (580299)</other_name>
    <other_name>HPV-16/18 L1 AS04 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and their parents/legally acceptable
             representatives can, and will, comply with the requirements of the protocol should be
             enrolled in the study.

          -  A female between, and including, 10 and 18 years of age at the time of the first
             vaccination.

          -  Written informed consent/assent obtained from the subject prior to enrolment. For
             subjects above the legal age of consent, written informed consent must be obtained
             from the subject. For subjects below legal age of consent, written informed consent
             obtained from the subject's parent/LAR, and written informed assent must be obtained
             from the subject.

          -  Healthy subjects, as established by medical history and history-directed physical
             examination, before entering into the study.

          -  Previously completed routine childhood vaccinations according to the recommended
             vaccination schedule at the time.

          -  Subjects must have a negative urine pregnancy test.

          -  Subject must be of non-childbearing potential, or if she is of childbearing potential,
             she must practice adequate contraception for 30 days prior to vaccination, have a
             negative pregnancy test and must agree to continue such precautions for two months
             after completion of the vaccination series. Subjects who reach menarche during the
             study, and therefore become of childbearing potential, must agree to follow the same
             precautions.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period (up to Month 12/13).

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after each dose of vaccine(s). Administration of
             routine vaccines up to 8 days before the first dose of study vaccine is allowed.
             Enrolment will be deferred until the subject is outside of specified window.

          -  A woman planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the study period and up to two months
             after the last vaccine dose.

          -  Pregnant or breastfeeding women.

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  Previous administration of components of the investigational vaccine

          -  Administration of a diphtheria, tetanus, pertussis (DTP) vaccine, diphtheria-tetanus
             (Td) booster or dTpa vaccine within the previous five years.

          -  Administration of a pre-school booster of Oral Polio Vaccine (OPV) or Inactivated
             Polio Virus (IPV) vaccine (4 or 5th dose) within the previous five years.

          -  Hypersensitivity to latex.

          -  Known acute or chronic, clinically significant neurologic, hepatic or renal functional
             abnormality or thrombocytopenia, as determined by previous physical examination or
             laboratory tests.

          -  Cancer or autoimmune disease under treatment.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of encephalopathy within seven days of administration of a previous dose of
             pertussis vaccine that is not attributable to another identifiable cause.

          -  Temperature of &gt;=40°C within 48 hours of receipt of a prior dose of DTP vaccine (DTPw
             and/or DTPa), not due to another identifiable cause.

          -  Collapse or shock-like state within 48 hours of receipt of a prior dose of DTP vaccine
             (DTPw and/or DTPa).

          -  Seizures with or without fever within three days of a prior dose of DTP vaccine
             (Diphtheria, Tetanus, whole cell Pertussis vaccine DTPw and/or Diphtheria, Tetanus,
             acellular Pertussis vaccine DTPa).

          -  Persistent, inconsolable crying lasting &gt;=3 hours, occurring within 48 hours of a
             prior dose of DTP vaccine (DTPw and/or DTPa).

          -  Severe Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoid
             within the previous 10 years.

          -  Known exposure to diphtheria or household exposure to pertussis within 30 days before
             (i.e., Day 0-29) vaccination with Diphtheria, Tetanus, acellular Pertussis and
             inactivated polio virus vaccine (dTpa-IPV).

          -  Diphtheria and/or tetanus and/or pertussis and/or polio diagnosed within 30 days
             before (i.e., Day 0-29) vaccination with dTpa-IPV.

          -  Presence of a contra-indication to vaccination according to the product leaflet of the
             commercially available dTpa-IPV vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period. Enrolment will be postponed until the subject is outside the specified window.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auch</city>
        <zip>32000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essey les Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evreux</city>
        <zip>27000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luynes</city>
        <zip>37230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montbrison</city>
        <zip>42600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pont de L'Arche</city>
        <zip>27340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vieux Condé</city>
        <zip>59690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Offenburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rheinstetten</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nordhausen</city>
        <state>Thueringen</state>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Schwarz T et al. Co-administration of AS04-adjuvanted HPV-16/18 cervical cancer vaccine with DTPA-IPV in 10-18 year old girls: Month 7 results from a randomized trial. Abstract presented at the 27th annual ESPID meeting, Brussels, Belgium, 9-13 June 2009.</citation>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <results_first_submitted>November 12, 2009</results_first_submitted>
  <results_first_submitted_qc>July 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2010</results_first_posted>
  <disposition_first_submitted>August 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2009</disposition_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Papillomavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108464</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix + Boostrix Polio Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
        </group>
        <group group_id="P3">
          <title>Boostrix Polio → Cervarix Group</title>
          <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix + Boostrix Polio Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
        </group>
        <group group_id="B3">
          <title>Boostrix Polio → Cervarix Group</title>
          <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="248"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="248"/>
            <count group_id="B4" value="751"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Active phase (up to Month 7/8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.59"/>
                    <measurement group_id="B2" value="14.0" spread="2.43"/>
                    <measurement group_id="B3" value="13.9" spread="2.47"/>
                    <measurement group_id="B4" value="13.9" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety follow-up (up to Month 12/13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.58"/>
                    <measurement group_id="B2" value="13.9" spread="2.41"/>
                    <measurement group_id="B3" value="13.8" spread="2.46"/>
                    <measurement group_id="B4" value="13.9" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="248"/>
                    <measurement group_id="B4" value="751"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected Against Diphtheria and Tetanus</title>
        <description>Seroprotection against diphtheria and tetanus is defined as anti-diphtheria and anti-tetanus antibody titres greater than or equal to 0.1 International Units per Milliliter (≥ 0.1 IU/mL).</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected Against Diphtheria and Tetanus</title>
          <description>Seroprotection against diphtheria and tetanus is defined as anti-diphtheria and anti-tetanus antibody titres greater than or equal to 0.1 International Units per Milliliter (≥ 0.1 IU/mL).</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="238"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin Toxoid (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
        <description>Titers are given as geometric mean titers (GMTs) calculated on all subjects and expressed as Enzyme-linked Immunosorbent Assay Units per Milliliter (EL.U/mL).</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin Toxoid (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
          <description>Titers are given as geometric mean titers (GMTs) calculated on all subjects and expressed as Enzyme-linked Immunosorbent Assay Units per Milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (n=238, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="84.2" lower_limit="73.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="75.4" lower_limit="65.6" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (n=240, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="611.7" lower_limit="553.6" upper_limit="675.9"/>
                    <measurement group_id="O3" value="615.2" lower_limit="552.3" upper_limit="685.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (n=239, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="426.2" lower_limit="368.1" upper_limit="493.4"/>
                    <measurement group_id="O3" value="360.0" lower_limit="299.3" upper_limit="433.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected Against Poliovirus Type 1 (Polio 1), Polio 2 and Polio 3</title>
        <description>Seroprotection against polio 1, 2 and 3 is defined as anti-polio 1, 2 and 3 antibody titers greater than or equal to 8 Effective Dose 50% (≥ 8 ED50).</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio and with available results for the defined antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected Against Poliovirus Type 1 (Polio 1), Polio 2 and Polio 3</title>
          <description>Seroprotection against polio 1, 2 and 3 is defined as anti-polio 1, 2 and 3 antibody titers greater than or equal to 8 Effective Dose 50% (≥ 8 ED50).</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio and with available results for the defined antigen.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polio 1 (n=240, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 2 (n=240, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 3 (n=239, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-HPV-18 Antibodies After Completing the Cervarix Vaccination Course</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>One month post Cervarix Dose 3 (Month 7/8)</time_frame>
        <population>Analysis was performed on the Month 7/8 According-to-Protocol (ATP) cohort for analysis of immunogenicity on subjects with available results for the defined antibody.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-HPV-18 Antibodies After Completing the Cervarix Vaccination Course</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed on the Month 7/8 According-to-Protocol (ATP) cohort for analysis of immunogenicity on subjects with available results for the defined antibody.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n=198, 202, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n=191, 204, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="203"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies After Incomplete Cervarix Vaccination Course</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>One month post Dose 1</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on subjects from the Cervarix and Cervarix + Boostrix Polio groups with available results for the defined antibody.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies After Incomplete Cervarix Vaccination Course</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on subjects from the Cervarix and Cervarix + Boostrix Polio groups with available results for the defined antibody.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n=198, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n=191, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies After Completing the Cervarix Vaccination Course</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
        <time_frame>One month post Cervarix Dose 3 (Month 7/8)]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies After Completing the Cervarix Vaccination Course</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n= 213, 222, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18363.6" lower_limit="16243.0" upper_limit="20761.0"/>
                    <measurement group_id="O2" value="15370.2" lower_limit="13350.9" upper_limit="17694.8"/>
                    <measurement group_id="O3" value="14089.5" lower_limit="12460.9" upper_limit="15930.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n= 210, 218, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7032.8" lower_limit="6220.7" upper_limit="7950.9"/>
                    <measurement group_id="O2" value="6630.4" lower_limit="5768.0" upper_limit="7621.6"/>
                    <measurement group_id="O3" value="5135.0" lower_limit="4537.3" upper_limit="5811.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-diphtheria and Anti-tetanus Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) and expressed as IU/mL.</description>
        <time_frame>One month after vaccination with Boostrix-Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Anti-diphtheria and Anti-tetanus Antibodies</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) and expressed as IU/mL.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.085" lower_limit="4.551" upper_limit="5.681"/>
                    <measurement group_id="O3" value="5.466" lower_limit="4.896" upper_limit="6.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.552" lower_limit="7.889" upper_limit="9.272"/>
                    <measurement group_id="O3" value="9.039" lower_limit="8.321" upper_limit="9.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibody Titers Above 1.0 International Units Per Milliliter (IU/mL)</title>
        <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed include 1.0 IU/mL.</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibody Titers Above 1.0 International Units Per Milliliter (IU/mL)</title>
          <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed include 1.0 IU/mL.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-poliovirus Type 1 (Anti-polio 1), Anti-polio 2 and Anti-polio 3 Antibody Titers</title>
        <description>Titers are given as Geometric Mean Titers (GMTs). The titer is a serum dilution giving 50 percent reduction of signal compared to control without serum.</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-poliovirus Type 1 (Anti-polio 1), Anti-polio 2 and Anti-polio 3 Antibody Titers</title>
          <description>Titers are given as Geometric Mean Titers (GMTs). The titer is a serum dilution giving 50 percent reduction of signal compared to control without serum.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-polio 1 (n=240, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2045.1" lower_limit="1714.7" upper_limit="2439.2"/>
                    <measurement group_id="O3" value="2390.5" lower_limit="2021.4" upper_limit="2826.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 2 (n=240, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2151.1" lower_limit="1806.5" upper_limit="2561.6"/>
                    <measurement group_id="O3" value="2158.1" lower_limit="1821.3" upper_limit="2557.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 3 (n=239, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2777.2" lower_limit="2376.5" upper_limit="3245.4"/>
                    <measurement group_id="O3" value="2732.5" lower_limit="2318.0" upper_limit="3221.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Booster Response to Diphtheria and Tetanus</title>
        <description>Booster responses to diphtheria and tetanus were defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off value of 0.1 International Units per Milliliter): antibody titers at least four times the cut-off (post-vaccination titer greater than or equal to 0.4 IU/mL), and
For initially seropositive subjects (pre-vaccination titer greater than or equal to 0.1 IU/mL): an increase in antibody titers of at least four times the pre-vaccination titer.</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Booster Response to Diphtheria and Tetanus</title>
          <description>Booster responses to diphtheria and tetanus were defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off value of 0.1 International Units per Milliliter): antibody titers at least four times the cut-off (post-vaccination titer greater than or equal to 0.4 IU/mL), and
For initially seropositive subjects (pre-vaccination titer greater than or equal to 0.1 IU/mL): an increase in antibody titers of at least four times the pre-vaccination titer.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Booster Response to Pertussis Toxoid (PT), Pertactin Toxoid (PRN) and Filamentous Hemagglutinin (FHA)</title>
        <description>Booster response to PT, FHA and PRN were defined as:
For initially seronegative subjects [pre-vaccination titer below cut-off value of 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)]: antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer above 20 EL.U/mL: an increase in antibody titers of at least 2 times the pre-vaccination titer.</description>
        <time_frame>One month after vaccination with Boostrix Polio</time_frame>
        <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Booster Response to Pertussis Toxoid (PT), Pertactin Toxoid (PRN) and Filamentous Hemagglutinin (FHA)</title>
          <description>Booster response to PT, FHA and PRN were defined as:
For initially seronegative subjects [pre-vaccination titer below cut-off value of 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)]: antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer above 20 EL.U/mL: an increase in antibody titers of at least 2 times the pre-vaccination titer.</description>
          <population>Analysis was performed on the Month 1 According-to-Protocol (ATP) cohort for analysis of immunogenicity and only on those subjects vaccinated with Boostrix Polio.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT (n=236, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA (n=235, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN (n=238, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.
Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
        <time_frame>During the 7-day period (Day 0-6) following each vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site.
Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
        <time_frame>During the 30-day period (Day 0-29) following vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
          <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (MSAEs)</title>
        <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes. MSAEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
        <time_frame>During the active phase of the study (up to Month 7/8) and during the safety follow-up (up to Month 12/13)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort (for the active phase) and on the Extended Safety Follow-up Vaccinated Cohort (for the safety follow-up).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (MSAEs)</title>
          <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes. MSAEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort (for the active phase) and on the Extended Safety Follow-up Vaccinated Cohort (for the safety follow-up).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NOCDs [Active phase] (n=248, 255, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCDs [Safety follow-up] (n=244, 250, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSAEs [Active phase] (n=248, 255, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSAEs [Safety follow-up] (n=244, 250, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the active phase of the study (up to Month 7/8) and during the safety follow-up (up to Month 12/13)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort (for the active phase) and on the Extended Safety Follow-up Vaccinated Cohort (for the safety follow-up).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Boostrix Polio Group</title>
            <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Boostrix Polio → Cervarix Group</title>
            <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort (for the active phase) and on the Extended Safety Follow-up Vaccinated Cohort (for the safety follow-up).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active phase (n=248, 255, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety follow-up (n=244, 250, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 7 day follow-up period after any vaccination for other (non-serious) adverse events. During the entire study period (12 months for Cervarix and Cervarix + Boostrix groups and 13 months for Cervarix → Boostrix group) for serious adverse events.</time_frame>
      <desc>For other (non-serious) adverse events collected by systematic assessment, the number of subjects at risk corresponds to the number of subjects from the Total Vaccinated Cohort with a documented dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix + Boostrix Polio Group</title>
          <description>Subjects who received GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.</description>
        </group>
        <group group_id="E3">
          <title>Boostrix Polio → Cervarix Group</title>
          <description>Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) at Month 1, 2 and 7.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Fever (above 37.5 degree Celsius)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

